Study Evaluating Etanercept in Moderate to Severe Asthma

Phase 2 Completed 120 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.

Timeline

Start: 2005-05
Primary completion: 2006-07
Completion: 2006-07

Outcome

Missed primary endpoint

paper No significant differences were observed between ETN and placebo for any of the efficacy end-points. PMID 21109557 ↗

Publications

Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, Nelson H, Raible D. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011 Jun;37(6):1352-9. doi: 10.1183/09031936.00063510. Epub 2010 Nov 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	25 mg	Subcutaneous